Leap Therapeutics 13G Filing Shows Gilead Sciences, Inc. Reported A 13.9% Stake In The Co As Of April 10, 2024
Leap Therapeutics 13G Filing Shows Gilead Sciences, Inc. Reported A 13.9% Stake In The Co As Of April 10, 2024
Top 10 Stocks With Upwards and Downwards Daily Percentage Change - Piper Sandler
Leap Therapeutics To Sell $40 Mln Of Shares In Private Placement; Stock Up Over 14%
Press Release: Leap Therapeutics Announces $40 Million Private Placement
Leap Therapeutics Announces $40 Million Private Placement PR Newswire CAMBRIDGE, Mass., April 11, 2024 Net proceeds, along with existing cash, cash equivalents, and marketable securities are expect
Leap Therapeutics Announces $40 Million Private Placement
Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and developme
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersXTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 13.9% to $2.71 during Wednesday's after-market session. The market value of their outstanding shares is at $14.7 million. Leap Thera
Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating
Leap Therapeutics (LPTX) has an average outperform rating and price target range of $7 to $16, according to analysts polled by Capital IQ.
Leap Therapeutics Is Maintained at Outperform by Baird
Leap Therapeutics Is Maintained at Outperform by Baird
Baird Maintains Outperform on Leap Therapeutics, Lowers Price Target to $9
Baird analyst Joel Beatty maintains Leap Therapeutics (NASDAQ:LPTX) with a Outperform and lowers the price target from $11 to $9.
HC Wainwright & Co. Reiterates Buy on Leap Therapeutics, Maintains $7 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Leap Therapeutics (NASDAQ:LPTX) with a Buy and maintains $7 price target.
Leap Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/19/2024 216.74% HC Wainwright & Co. → $7 Reiterates Buy → Buy 11/20/2023 442.99% Mizuho $20 → $12 Maint
Leap Therapeutics: Promising Clinical Outcomes and Upcoming Catalysts Bolster Buy Rating
Leap Therapeutics' Success Tied to Partner NovaRock's Commitment in Asian Markets
Leap Therapeutics: Q4 Earnings Insights
Leap Therapeutics (NASDAQ:LPTX) reported its Q4 earnings results on Monday, March 18, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsLeap Therapeutics beat estimate
Leap Therapeutics Files for $200M Mixed Shelf Offering
Leap Therapeutics GAAP EPS of -$0.46 Beats by $0.10
Leap Therapeutics 4Q Loss/Shr 46c >LPTX
Leap Therapeutics 4Q Loss/Shr 46c >LPTX
Press Release: Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass., March 18, 2024 CAMBRIDGE, Mass., March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, Mass., March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financia
Maintaining Buy Rating on Leap Therapeutics: Promising DKN-01 Trials and Undervalued Market Potential
No Data